Bli medlem
Bli medlem

Du är här


Oncology Venture: Oncology Ventures' new rights issue oversubscribed

On November 10th, 2016, the subscription period in Oncology Venture
Sweden AB's ("Oncology Venture") rights issue ended, in which the
general public was given the opportunity to subscribe for shares as
well. Through the rights issue 774,984 new shares will be issued and
Oncology Venture will thus be provided approximately SEK 21.4 million
after issue costs. Issue costs amounted to approximately SEK 1.1
million. Contract notes are scheduled to be sent out today, November
16th, 2016. Including subscription commitments, the new rights issue
was signed to approximately SEK 60.3 million, representing a
subscription rate of about 268 %.

"We are in an important stage of development and are of course very
grateful for the interest in the new rights issue. Through the raised
capital, we can fund product manufacturing for clinical trials that
are being conducted in accordance with the development agreement with
Cadila Pharmaceuticals Ltd. which covers joint development of
LiPlaCis® and secure rights to three interesting products for
treatment of cancer in women for 2X Oncology Inc. - an American
spinout (Special Purpose Vehicle) from Oncology Venture. In addition,
the raised capital will also partially fund the development of a
fourth drug candidate, including screening, personnel costs and
completion of license", says Peter Buhl Jensen, Adjunct Professor,
MD, PhD and CEO of Oncology Venture.

"We face a number of exciting projects - all with great potential. We
now have the opportunity to, in a focused way, increase the pace of
the business further - something that significantly increases the
likelihood of achieving success in the business", Dr. Buhl Jensen
further commented.

Subscription and allotment of rights issue

In total, the received notifications correspond to approximately SEK
60.3 million (including subscription undertaking). 770,567 shares
(approximately 99% of the issue volume) will be given to subscribers
with preferential rights. Those who receive shares without
subscription rights will receive contract notes, which are expected
to be sent out today, November 16th, 2016. Signatories which are not
allocated shares will not receive contract notes.

Shares and share capital

After the new rights issue registration, the total number of shares in
Oncology Venture will increase to 10,074,794 shares. The share
capital after the registration will be SEK 1 410 471.16.

Trading in BTA

Trading in BTAs (paid subscription share) will take place on
AktieTorget until the Swedish Companies Registration Office has
registered the new rights issue. Registration is expected to occur in
early December 2016.

Financial Advisor

Sedermera Fondkommission has acted as financial advisor to Oncology
Venture in the new rights issue.

For questions related to the new issue, please contact:

Sedermera Fondkommission

Telephone: 040-615 14 10


For further Information about Oncology Venture, please contact:

Ulla Hald Buhl, COO, IR & Communication Peter Buhl Jensen, CEO

Telephone +45 21 70 10 49 Telephone: +45 21 60 89 22

E-mail: E-mail:

This information is information that Oncology Venture Sweden AB is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of
the contact person set out above, on November 16th, 2016.

About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has a license to use Drug Response
Prediction - DRP™ - in order to significantly increase the
probability of success in clinical trials. DRP™ has proven its
ability to provide a statistically significant prediction of clinical
outcomes from drug treatment in cancer patients in 29 of the 37
clinical studies that were examined. The Company uses a model that
alters the odds in comparison with traditional pharmaceutical
development. Instead of treating all patients with a particular type
of cancer, patients are screened first and only those who are most
likely to respond to the treatment will be treated. Via a more well
defined patient group, the risk and costs are reduced while the
development process becomes more efficient.

The current product portfolio: LiPlaCis™, for Breast Cancer,
Irofulven, developed from a fungus, for Prostate Cancer, and APO010,
an immuno-oncology product for Multiple Myeloma.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.